Ra Pharmaceuticals(RARX)

旭日待东升2019-10-11 11:53

昨日美国医药行业大事：
$Ra Pharmaceuticals(RARX)$ 果然是好标的，之前持续上涨，刚刚回调，就被UCB作价21亿收购了。昨日涨幅100%
$OncoSec医疗(ONCS)$ China Grand Pharma 投资2500万，收购44.2%的股份，还将可能以超4.5美元的价格收购余下股份。
$Reata制药(RETA)$ StiffL 给予买...查看全文

美港探案2019-10-10 23:53

$达美航空(DAL)$ 跌逾3%，尽管Q3盈利超预期；$Ra Pharmaceuticals(RARX)$ 暴涨逾100%，UCB将以21亿美元收购前者；PG&E大跌30%，因破产法官允许Elliot提出重组计划；3B家居大涨22%，任命前塔吉特高管为新任CEO；$如涵(RUHN)$ 招股书被指误导投资人，在美一个月遭逾10宗集体诉讼。查看全文

书白念2019-10-10 23:33

$Ra Pharmaceuticals(RARX)$ 厉害查看全文

美股马甲2019-10-10 23:00

$Ra Pharmaceuticals(RARX)$ 能不能把XBI重新拉起来……查看全文

chuminhua2019-10-10 21:11

$Ra Pharmaceuticals(RARX)$ $UCB(UCBJY)$ 10/10，UCB宣布以每股48美元，总计21亿美元现金收购Ra Pharma。前一天Ra Pharma的收盘价为22.70美元。Ra的C5抑制剂zilucoplan正在开展治疗重症肌无力（MG）的III期临床，该产品有望与Alexion的Soliris竞争。查看全文

英为财情Investing2019-10-10 20:43

$达美航空(DAL)$ 跌逾3%，尽管Q3盈利超预期；$Ra Pharmaceuticals(RARX)$ 暴涨逾100%，UCB将以21亿美元收购前者；PG&E大跌30%，因破产法官允许Elliot提出重组计划；3B家居大涨22%，任命前塔吉特高管为新任CEO；$如涵(RUHN)$ 招股书被指误导投资人，在美一个月遭逾10宗集体诉讼。查看全文

淘沙见金2019-10-10 18:42

$Ra Pharmaceuticals(RARX)$ EU pharma quite active in H2 so far on M&As
July: Boehringer Ingelheim / Amal Tx, Zambon / Breath Tx
Aug: Bayer / BlueRock Tx
Sept: Lundbeck / Alder Biopharma, SOBI / Dova Pharma
Oct: UCB / Ra Pharma
延续了最近欧洲药企来抄底的主查看全文

牛唐2019-03-16 14:58

$Akari Therapeutics(AKTX)$ FDA同意coversin在HSCT-TMA适应症的关键阶段的实验设计，引发了翻倍的增长，如果后续数据好的话，未来市值有望跟相$Ra Pharmaceuticals(RARX)$ 、$奥麦罗制药(OMER)$ 相比查看全文

Apellis Pharmaceutical:补体分子C3抑制剂的价值

淘沙见金2017-11-09 11:56

(个人笔记，欢迎讨论)
Apellis Pharmaceutical $Apellis Pharmaceuticals, Inc.(APLS)$ 是一家生物制药临床研发公司，头号在研药物APL2是补体分子C3抑制剂，用于治疗各种自身免疫性疾病如年龄相关性黄斑变性(AMD)，PNH，自身免疫性溶血性贫血（Autoimmune hemolytic anemia，AIHA）和年龄相关...查看全文

$Ra Pharmaceuticals(RARX)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-05-09 AccNo: 0001047469-19-002989 Size: 305 KB 网页链接

$Ra Pharmaceuticals(RARX)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2019-05-09 AccNo: 0001104659-19-028271 Size: 134 KB 网页链接

$Ra Pharmaceuticals(RARX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-05-09 AccNo: 0001104659-19-027979 Size: 2 MB 网页链接

$Ra Pharmaceuticals(RARX)$ DEF 14A - Other definitive proxy statements Filed: 2019-04-26 AccNo: 0001047469-19-002631 Size: 690 KB 网页链接

$Ra Pharmaceuticals(RARX)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-04-26 AccNo: 0001104659-19-024060 Size: 269 KB 网页链接

$Ra Pharmaceuticals(RARX)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-03-08 AccNo: 0001144204-19-013072 Size: 148 KB 网页链接

$Ra Pharmaceuticals(RARX)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-03-07 AccNo: 0001047469-19-000968 Size: 6 MB 网页链接

$Ra Pharmaceuticals(RARX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-12 AccNo: 0000902219-19-000234 Size: 37 KB 网页链接

$Ra Pharmaceuticals(RARX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-08 AccNo: 0000215457-19-006577 Size: 13 KB 网页链接

$Ra Pharmaceuticals(RARX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-05 AccNo: 0001104659-19-005827 Size: 106 KB 网页链接